Show simple item record

dc.contributor.authorLevine, Richard J
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorHorowitz, Gary Leigh
dc.contributor.authorQian, Cong
dc.contributor.authorRomundstad, Pal R
dc.contributor.authorYu, Kai F
dc.contributor.authorHollenberg, Anthony Neil
dc.contributor.authorHellevik, Alf I
dc.contributor.authorAsvold, Bjorn O
dc.contributor.authorKarumanchi, Subbian Ananth
dc.date.accessioned2013-01-07T20:48:27Z
dc.date.issued2009
dc.identifier.citationLevine, Richard J., Lars J. Vatten, Gary L. Horowitz, Cong Qian, Pal R. Romundstad, Kai F. Yu, Anthony N. Hollenberg, Alf I. Hellevik, Bjorn O. Asvold, and S. Ananth Karumanchi. 2009. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: Nested case-control and population based study. British Medical Journal 339:b4336.en_US
dc.identifier.issn0959-8138en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10139593
dc.description.abstractObjective: To determine if pre-eclampsia is associated with reduced thyroid function during and after pregnancy. Design: Nested case-control study during pregnancy and population based follow-up study after pregnancy. Setting: Calcium for Pre-eclampsia Prevention trial of healthy pregnant nulliparous women in the United States during 1992-5, and a Norwegian population based study (Nord-Trondelag Health Study or HUNT-2) during 1995-7 with linkage to the medical birth registry of Norway. Participants: All 141 women (cases) in the Calcium for Pre-eclampsia Prevention trial with serum measurements before 21 weeks’ gestation (baseline) and after onset of pre-eclampsia (before delivery), 141 normotensive controls with serum measurements at similar gestational ages, and 7121 women in the Nord-Trondelag Health Study whose first birth had occurred in 1967 or later and in whom serum levels of thyroid stimulating hormone had been subsequently measured. Main outcome measures: Thyroid function tests and human chorionic gonadotrophin and soluble fms-like tyrosine kinase 1 concentrations in the Calcium for Pre-eclampsia Prevention cohort and odds ratios for levels of thyroid stimulating hormone above the reference range, according to pre-eclampsia status in singleton pregnancies before the Nord-Trondelag Health Study. Results: In predelivery specimens of the Calcium for Pre-eclampsia Prevention cohort after the onset of pre-eclampsia, thyroid stimulating hormone levels increased 2.42 times above baseline compared with a 1.48 times increase in controls. The ratio of the predelivery to baseline ratio of cases to that of the controls was 1.64 (95% confidence interval 1.29 to 2.08). Free triiodothyronine decreased more in the women with pre-eclampsia than in the controls (case ratio to control ratio 0.96, 95% confidence interval 0.92 to 0.99). The predelivery specimens but not baseline samples from women with pre-eclampsia were significantly more likely than those from controls to have concentrations of thyroid stimulating hormone above the reference range (adjusted odds ratio 2.2, 95% confidence interval 1.1 to 4.4). Both in women who developed pre-eclampsia and in normotensive controls the increase in thyroid stimulating hormone concentration between baseline and predelivery specimens was strongly associated with increasing quarters of predelivery soluble fms-like tyrosine kinase 1 (P for trend 0.002 and <0.001, respectively). In the Nord-Trondelag Health Study, women with a history of pre-eclampsia in their first pregnancy were more likely than other women (adjusted odds ratio 1.7, 95% confidence interval 1.1 to 2.5) to have concentrations of thyroid stimulating hormone above the reference range (>3.5 mIU/l). In particular, they were more likely to have high concentrations of thyroid stimulating hormone without thyroid peroxidase antibodies (adjusted odds ratio 2.6, 95% confidence interval 1.3 to 5.0), suggesting hypothyroid function in the absence of an autoimmune process. This association was especially strong (5.8, 1.3 to 25.5) if pre-eclampsia had occurred in both the first and the second pregnancies. Conclusion: Increased serum concentration of soluble fms-like tyrosine kinase 1 during pre-eclampsia is associated with subclinical hypothyroidism during pregnancy. Pre-eclampsia may also predispose to reduced thyroid function in later years.en_US
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.isversionofdoi:10.1136/bmj.b4336en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778749/pdf/en_US
dash.licenseLAA
dc.titlePre-eclampsia, Soluble fms-like Tyrosine Kinase 1, and the Risk of Reduced Thyroid Function: Nested Case-Control and Population Based Studyen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBMJ: British Medical Journalen_US
dash.depositing.authorHorowitz, Gary Leigh
dc.date.available2013-01-07T20:48:27Z
dash.affiliation.otherHMS^Pathologyen_US
dash.affiliation.otherHMS^Health Sciences and Technologyen_US
dash.affiliation.otherHMS^Medicine- Beth Israel-Deaconessen_US
dash.affiliation.otherHMS^Obstetrics Gynecology and Repro. Bio. - BIDMCen_US
dash.affiliation.otherHMS^Medicine- Beth Israel-Deaconessen_US
dc.identifier.doi10.1136/bmj.b4336*
dash.contributor.affiliatedHorowitz, Gary Leigh
dash.contributor.affiliatedHollenberg, Anthony
dash.contributor.affiliatedVatten, Lars Johan
dash.contributor.affiliatedKarumanchi, Subbian


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record